Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis

被引：0

作者：

Coelho, Teresa ^{[1
]}

Whelan, Carol ^{[2
]}

Conceicao, Isabel ^{[3
,4
]}

Brannagan, Thomas ^{[5
]}

Wang, Annabel ^{[6
]}

Polydefkis, Michael ^{[7
]}

Dyck, Peter ^{[8
]}

Plante-Bordeneuve, Violaine ^{[9
]}

Berk, John ^{[10
]}

Merlini, Giampaolo ^{[11
]}

Obici, Laura ^{[11
]}

Drachman, Brian ^{[12
]}

Gorevic, Peter ^{[13
]}

Schmidt, Hartmut ^{[14
]}

Plana, Josep Maria Campistol ^{[15
]}

Gamez, Josep ^{[16
]}

Kristen, Arnt ^{[17
]}

Mazzeo, Anna ^{[18
]}

Narayana, Arvind ^{[19
]}

Olugemo, Kemi ^{[20
]}

Aquino, Peter ^{[21
]}

Benson, Merrill ^{[22
]}

Gertz, Morie ^{[23
]}

机构：

[1] Ctr Hosp Univ Porto, Dept Neurophysiol, Porto, Portugal

[2] Royal Free Hosp, Natl Amyloidosis Ctr, London, England

[3] CHULN, Hosp Santa Maria, Lisbon, Portugal

[4] Univ Lisbon, Dept Neurosci, Fac Med, Lisbon, Portugal

[5] Columbia Univ, Med Ctr, Peripheral Neuropathy Ctr, New York, NY USA

[6] Univ Calif Irvine, Dept Neurol, Orange, CA 92668 USA

[7] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA

[8] Mayo Clin, Peripheral Nerve Res Lab, Rochester, MN USA

[9] CHU Henri Mondor, Dept Neurol, Creteil, France

[10] Boston Univ, Amyloidosis Ctr, Boston, MA 02215 USA

[11] IRCCS Fdn Policlin San Matteo, Amyloidosis Ctr, Pavia, Italy

[12] Penn Presbyterian Med Ctr, Dept Cardiovasc Med, Philadelphia, PA USA

[13] Mt Sinai Med Ctr, Dept Rheumatol, New York, NY 10029 USA

[14] Muenster Univ Hosp, Dept Gastroenterol Hepatol Endocrinol Diabetol &, Munster, Germany

[15] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Barcelona, Spain

[16] Hosp Univ Vall dHebron, Dept Neurol, Barcelona, Spain

[17] Heidelberg Univ Hosp, Amyloidosis Ctr, Heidelberg, Germany

[18] Univ Messina, Dept Neurol, Messina, Italy

[19] Akcea Therapeut, Global Med Affairs, Boston, MA USA

[20] Akcea Therapeut, Clin Dev, Boston, MA USA

[21] Akcea Therapeut, Global Drug Safety & Pharmacovigilance, Boston, MA USA

[22] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[23] Mayo Clin, Bone Marrow Transplant Program, Rochester, MN USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2021年 / 429卷

关键词：

D O I：

10.1016/j.jns.2021.117867

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

117867

引用

页数：3

共 50 条

[41] A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Ivan Urits
Daniel Swanson
Michael C. Swett
Anjana Patel
Kevin Berardino
Ariunzaya Amgalan
Amnon A. Berger
Hisham Kassem
Alan D. Kaye
Omar Viswanath
Neurology and Therapy, 2020, 9 : 301 - 315
[42] Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
de Campos, Catarina Falcao
Conceicao, Isabel
DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 51 - 62
[43] Treatment satisfaction for gene silencing pharmacotherapies for the treatment of hereditary transthyretin amyloidosis with polyneuropathy
Kessler, Asia Sikora
Brown, Duncan
Llonch, Montserrat
Yarlas, Aaron
Mccausland, Kristen
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 233 - 233
[44] Inotersen improves quality of life, polyneuropathy, and cardiomyopathy in patients with hereditary transthyretin amyloidosis: results of the phase 3 study NEURO-TTR
Whelan, C.
Drachman, B.
Heitner, S.
Maurer, M.
Damy, T.
Judge, D.
Monia, B.
Hughes, S.
Kwoh, J.
Jung, B.
Ackermann, E.
Benson, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 361 - 361
[45] Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years
Barroso, Fabio A.
Judge, Daniel P.
Ebede, Ben
Li, Huihua
Stewart, Michelle
Amass, Leslie
Sultan, Marla B.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (03): : 194 - 204
[46] Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy
Merkel, Madeline
Danese, David
Chen, Chongshu
Wang, Jessie
Wu, Aozhou
Yang, Hongbo
Lin, Hollis
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1205 - 1214
[47] Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis
Benson, Merrill D.
Dasgupta, Noel R.
Monia, Brett P.
NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 25 - 30
[48] Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management
Alcantara, Monica
Mezei, Michelle M.
Baker, Steven K.
Breiner, Ari
Dhawan, Priya
Fiander, Amanda
Fine, Nowell M.
Hahn, Christopher
Katzberg, Hans D.
Khayambashi, Shahin
Massie, Rami
Matte, Genevieve
Putko, Brendan
Siddiqi, Zaeem
Delgado, Diego
Bril, Vera
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (01) : 7 - 18
[49] Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy
Ines, Monica
Coelho, Teresa
Conceicao, Isabel
Landeiro, Filipa
de Carvalho, Mamede
Costa, Joao
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (02): : 89 - 96
[50] Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO-TTR
Coelho, T.
Wang, A.
Waddington Cruz, M.
Polydefkis, M.
Dyck, P.
Scheinberg, M.
Plante-Bordeneuve, V.
Berk, J.
Barroso, F.
Adams, D.
Brannagan, T.
Whelan, C.
Merlini, G.
Drachman, B.
Heitner, S.
Conceicao, I.
Schmidt, H.
Vita, G.
Gamez, J.
Gane, E.
Gorevic, P.
Souza Bulle Oliveira, A.
Monia, B.
Gertz, M.
Benson, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 376 - 376

← 1 2 3 4 5 →

Efficacy and safety with &gt;3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis

Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis